Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Electronic records and signatures

This article was originally published in The Tan Sheet

Executive Summary

Notice of a public meeting on "industry's experience in implementing the technical provisions of regulations on electronic records and electronic signatures" published in the Feb. 22 Federal Register. Cosponsored by FDA and the Parenteral Drug Association, the meeting will be held June 19-20 at the Wyndham Franklin Plaza Hotel in Philadelphia. Those wanting to make presentations must submit abstracts of their talks by March 19 to Angie Fischer, PDA, 7500 Old Georgetown Rd., Suite 620, Bethesda, Md. 20814. For more information, contact Steven Solomon, FDA Office of Enforcement, Office of Regulatory Affairs, at (301)-827-0386. FDA's final reg on electronic records and signatures became effective in August 1997. The meeting will be used to help develop future guidances

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel